NCT02207725View on ClinicalTrials.gov

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

September 30, 2015

Conditions
Bleeding
Interventions
BIOLOGICAL

Andexanet

OTHER

Placebo

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT02207725 - A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | Biotech Hunter | Biotech Hunter